Cancer Pain & CINV
Our unique formulation will undergo Phase I - III trials for market authorisation. In regions where a "wellness" approach has been taken, we will only start sales of our product at the completion of our Phase II trial clearly demonstrating our unique efficacy and dosing guidance for patients and medical practitioners security, comfort and of course unrivalled efficacy. Our unique WaferMat delivery
pool
I'm a paragraph. Click here to add
your own text and edit me.
sauna
I'm a paragraph. Click here to add
your own text and edit me.
hammam
I'm a paragraph. Click here to add
your own text and edit me.
Doctors and patients have been searching for targeted medications that are fast acting, pharmaceutically consistent and easy to take. Through a deep clinical pedigree in novel drug development, GreenTech is driving innovation by combining cutting edge delivery science with selected botanically derived active pharmaceutical ingredients (API's), repurposed generic compounds or bio-actives that demonstrate improved performance when loaded in GreenTech ADDS's. GreenTech's unique formulation and state of the art sonic nano-emulsion technologies have resulted in new and repurposed drug candidates targeting the following initial disease areas:
Breakthrough Pain
(BTcP) & CINV
Rx
Our unique formulation will undergo robust clinical trials for market authorisation. The final WaferMat product line is likely to ensure rapid onset of action combined through a revolutionary buccal adhesion profile, with an advanced formulation resulting in fast acting &
targeted relief for patients. Significant harm and use reduction over opioids is expected.
Sleep & Anxiety
(Circadian Rhythm Disorders)
OTC
GreenTech's unique formulation of CBD and Melatonin should help patients with sleep disorders sleep more naturally. We will be conducting safety and efficacy trials before driving production, a first in the OTC / Wellness Sleep & Anxiety area to combine the benefits of cannabinoid and melatonin API's, targeted delivery with clinically driven drug development. Our thoroughly researched sleep formulation will displace alternatives through rapid onset of action and high bioavailability by incorporating the latest botanical extraction & the advantages of advanced drug delivery embedded in the production and IP of our offerings.
Chronic Wound Care
By bringing together a team of leading wound care specialists from around the globe, GreenTech's unique bio-active formulations are designed to impact the chronic wound care market, targeting wound closure in the most recalcitrant wounds; serious cases which often may lead to surgery or even amputation. QoL is substantially impacted in this disease category and is considered a critical area of unmet need by both the FDA and EMA combined. Our first product line targets Veinous Leg (VLU) with research being conducted for Pressure Ulcers (PU) and Diabetic Foot Ulcers (DFU) using our same delivery technology. Our chronic wound team is determined to improve current standard of care regimens which still result in over 60,000 deaths a year in the USA alone, with correspondingly high amputation levels. By targeting the peri-wound as well as the wound bed using PPAR, anti-inflammation and antimicrobial mechanisms of action, our chronic wound care gel will play a major role in this largely overlooked market segment.
"Advanced Impact Generics"
By using our secured patented advanced drug delivery platforms, GreenTech has created and is developing several novel generic medications where we intend on improving efficacy and onset timing through enhanced drug performance resulting in early stage revenues in our risk mitigation strategy. Our extensive international trial platform will bring these products to market with strategic commercial partners in all regions.